Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (821-830 of 1,482) with videos related to

Pageof 149
Sort By:
European Heart Journal|March 18, 2022
Sudden cardiac death in congenital heart diseasePaul Khairy, Michael J Silka, Jeremy P Moore, et al.
Cancer|April 6, 2021
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinibKiyomi Morita, Hagop M Kantarjian, Koji Sasaki, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 25, 2024
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeOren Pasvolsky, Rima M Saliba, Uday R Popat, et al.
Leukemia Research|November 9, 2015
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesTalha Badar, Keyur P Patel, Philip A Thompson, et al.
Journal of Clinical Laboratory Analysis|June 2, 2017
Defining the clinical relevance of red blood cell autoantibodies by Monocyte Monolayer AssayMarina C A V Conrado, Amanda N D'Avila, Juliana B Vieira, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
The Journal of Clinical Investigation|March 4, 2020
DNA hypermethylation during tuberculosis dampens host immune responsivenessAndrew R DiNardo, Kimal Rajapakshe, Tomoki Nishiguchi, et al.
Leukemia|June 21, 2020
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemiaMansour Alfayez, Ghayas C Issa, Keyur P Patel, et al.
American Journal of Hematology|August 5, 2021
Development of TP53 mutations over the course of therapy for acute myeloid leukemiaYasmin Alwash, Joseph D Khoury, Mehrnoosh Tashakori, et al.
Vox Sanguinis|June 12, 2019
Prevalence and laboratorial determinants of the clinical relevance of antibodies of undetermined specificityMarina Cavalcanti de Albuquerque da Veiga Conrado, Regina A Cardoso, Marcia Regina Dezan, et al.
Pageof 149

Showing results (821-830 of 1,482) with videos related to

Sort By:
Pageof 149
European Heart Journal|March 18, 2022
Sudden cardiac death in congenital heart diseasePaul Khairy, Michael J Silka, Jeremy P Moore, et al.
Cancer|April 6, 2021
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinibKiyomi Morita, Hagop M Kantarjian, Koji Sasaki, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 25, 2024
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeOren Pasvolsky, Rima M Saliba, Uday R Popat, et al.
Leukemia Research|November 9, 2015
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesTalha Badar, Keyur P Patel, Philip A Thompson, et al.
Journal of Clinical Laboratory Analysis|June 2, 2017
Defining the clinical relevance of red blood cell autoantibodies by Monocyte Monolayer AssayMarina C A V Conrado, Amanda N D'Avila, Juliana B Vieira, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
The Journal of Clinical Investigation|March 4, 2020
DNA hypermethylation during tuberculosis dampens host immune responsivenessAndrew R DiNardo, Kimal Rajapakshe, Tomoki Nishiguchi, et al.
Leukemia|June 21, 2020
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemiaMansour Alfayez, Ghayas C Issa, Keyur P Patel, et al.
American Journal of Hematology|August 5, 2021
Development of TP53 mutations over the course of therapy for acute myeloid leukemiaYasmin Alwash, Joseph D Khoury, Mehrnoosh Tashakori, et al.
Vox Sanguinis|June 12, 2019
Prevalence and laboratorial determinants of the clinical relevance of antibodies of undetermined specificityMarina Cavalcanti de Albuquerque da Veiga Conrado, Regina A Cardoso, Marcia Regina Dezan, et al.
Pageof 149